Company Profile

VaxGen Inc
Profile last edited on: 5/13/2024      CAGE: 34WK3      UEI: XNSACMACJLV3

Business Identifier: Infectious disease vaccines
Year Founded
1995
First Award
2000
Latest Award
2004
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

349 Oyster Point Boulevard
South San Fransisco, CA 94080
   (650) 624-1000
   pberman@vaxgen.com
   www.vaxgen.com
Location: Multiple
Congr. District: 15
County: San Mateo

Public Profile

Having been acquired by Oxigene in 2009, in July 2010, Vaxgen acquired diaDexus in a reverse merger and effectively ceased operations. Spun out of Genentech and orginally known as Genenvax Inc., VaxGen, Inc. had been a biopharmaceutical company engaged in the development, of biologic products for the prevention and treatment specifically vaccines against anthrax, smallpox and HIV/AIDS . Earlier the firm had been the single-largest shareholder in Celltrion Inc., a joint venture formed to build biopharmaceutical manufacturing operations to produce complex proteins made through mammalian-cell fermentation. In the 1990s VaxGen developed, and began trials of, an AIDS vaccine in collbaoration with National Institute of Allergy and Infectious Diseases (NIAID) investigation the body's immune response to the vaccine. In 2003 it was announced that the preliminary trials of the vaccine, conducted in Thailand and Indianapolis, IN had been unsuccessful. Vaxgen shifted focus to a new form of Anthrax Vaccine with a large contract from the Project Bioshiled Act to provide the vaccine under the Project Bioshield Act.That contract was subsequently withdrawn

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
250-500
Revenue Range
20M-50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : VXGN
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $376,445
Project Title: Correlates of Protection Against HIV-1 Infection
2004 2 NIH $2,143,444
Project Title: Vaccines Designed from Analysis of Recent HIV Infections
2002 2 NIH $1,130,950
Project Title: Subtype C Hiv Antigen: Multivalent & Prime-Boost Regimen

Key People / Management

  Donald Francis -- President

  Lance Gordon -- CEO

  Phillip W Berman

  Faruk M Sinangil

Company News

There are no news available.